Chen Jie-Min, Zhong Yao-Tang, Tu Chang, Lan Jun
Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, Dongguan 523326, Guangdong Province, China.
World J Clin Cases. 2020 Aug 26;8(16):3458-3464. doi: 10.12998/wjcc.v8.i16.3458.
The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias.
To investigate the levels and significance of serum fibroblast growth factor 23 (FGF-23) and miR-208b in patients with atrial fibrillation and their relationship with prognosis.
From May 2018 to October 2019, 240 patients with atrial fibrillation were selected as an observation group, including 134 with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation; 150 patients with healthy sinus rhythm were selected as a control group. The serum levels of FGF-23 and miR-208b in the two groups were measured. In the observation group, cardiac parameters were determined by echocardiography.
The serum levels of FGF-23 and miR-208b in the observation group were 210.20 ± 89.60 ng/mL and 5.30 ± 1.22 ng/mL, which were significantly higher than the corresponding values in the control group ( < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were 234.22 ± 70.05 ng/mL and 5.83 ± 1.00 ng/mL, which were significantly higher than the corresponding values in patients with paroxysmal atrial fibrillation ( < 0.05). The left atrial dimension (LAD) of patients with persistent atrial fibrillation was 38.81 ± 5.11 mm, which was significantly higher than that of patients with paroxysmal atrial fibrillation ( > 0.05). The serum levels of FGF-23 and miR-208b were positively correlated with the LAD ( = 0.411 and 0.382, < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, which were significantly higher than the corresponding values in patients without a MACE ( < 0.05).
The serum levels of FGF-23 and miR-208b are increased in patients with atrial fibrillation and are related to the type of disease, cardiac parameters, and prognosis.
心房颤动的发病率和患病率逐年上升，这种病症是最常见的临床心律失常之一。
探讨心房颤动患者血清成纤维细胞生长因子23（FGF - 23）和miR - 208b的水平及意义，以及它们与预后的关系。
选取2018年5月至2019年10月的240例心房颤动患者作为观察组，其中阵发性心房颤动134例，持续性心房颤动106例；选取150例健康窦性心律者作为对照组。检测两组血清FGF - 23和miR - 208b水平。在观察组中，通过超声心动图测定心脏参数。
观察组血清FGF - 23和miR - 208b水平分别为210.20±89.60 ng/mL和5.30±1.22 ng/mL，显著高于对照组相应值（<0.05）。观察组中，持续性心房颤动患者血清FGF - 23和miR - 208b水平分别为234.22±70.05 ng/mL和5.83±1.00 ng/mL，显著高于阵发性心房颤动患者相应值（<0.05）。持续性心房颤动患者的左心房内径（LAD）为38.81±5.11 mm，显著高于阵发性心房颤动患者（>0.05）。血清FGF - 23和miR - 208b水平与LAD呈正相关（r = 0.411和0.382，<0.05）。观察组中，发生重大心血管事件（MACE）患者的血清FGF - 23和miR - 208b水平分别为243.30±72.29 ng/mL和6.12±1.12 ng/mL，显著高于未发生MACE患者相应值（<0.05）。
心房颤动患者血清FGF - 23和miR - 208b水平升高，且与疾病类型、心脏参数及预后有关。
